News & Press Releases
Jan
16
2024
CULLGEN ANNOUNCES ADDITIONS TO BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD
SAN DIEGO, January 16, 2024 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.
Oct
15
2023
CULLGEN AND ASTELLAS HONORED WITH 2023 LES DEALS OF DISTINCTION AWARD
SAN DIEGO, October 15, 2023 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has earned a Deals of Distinction award from the Licensing Executives Society (LES) for its Collaboration, Option and License Agreement with Astellas announced earlier in 2023.
July
27
2023
CULLGEN ANNOUNCES FIRST-IN-HUMAN DOSE IN PHASE I/II TRIAL OF CG001419, A FIRST-IN-CLASS TRK PROTEIN DEGRADER FOR TREATMENT OF CANCER PATIENTS
CG001419 is Cullgen’s first protein degrader to enter clinical development
SAN DIEGO and SHANGHAI, July 27, 2023 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has initiated dosing with its orally bioavailable pan-TRK degrader, CG001419, in a Phase I/II clinical trial for patients with solid tumors.
June
14
2023
ASTELLAS AND CULLGEN ENTER INTO STRATEGIC COLLABORATION AND OPTION AGREEMENT TO ADVANCE INNOVATIVE TARGETED PROTEIN DEGRADERS
TOKYO and SAN DIEGO, June 14, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Cullgen Inc. (President and CEO: Ying Luo, Ph.D., “Cullgen”) today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.
May
08
2023
CULLGEN RAISES $40 MILLION IN NEW FINANCING LED BY ASTRAZENECA-CICC FUND
SAN DIEGO and SHANGHAI, May 08, 2023 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITETM platform of targeted protein degradation technology, today announced that it has raised $40 million in new financing.
Aug
09
2022
CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF TRK DEGRADER TO BEGIN CLINICAL TRIALS
SAN DIEGO, California, USA, August 9, 2022 Cullgen Inc., a leading biotechnology company developing targeted protein degraders based on its proprietary uSMITE™ platform technology, today announced that the Chinese National Medical Products Administration (NMPA) has allowed the Investigational New Drug (IND) application for CG001419, a TRK degrader for the treatment of solid tumors. CG001419 is a first-in-class, selective, potent oral targeted protein degrader for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast, and pancreatic cancers.
Sept
23
2021
NATURE REVIEWS CANCER SELECTS PUBLICATION BY CULLGEN CO-FOUNDERS FOR INCLUSION IN 20TH ANNIVERSARY ISSUE
SAN DIEGO, California, USA, September 23, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, is honored that the article co-authored by Cullgen founders Dr. Jian Jin and Dr. Yue Xiong entitled “Advancing Targeted Protein Degradation for Cancer Therapy”, has been included in the 20th Anniversary Issue of the prestigious journal, Nature Reviews Cancer.
June
16
2021
CULLGEN ANNOUNCES PROMINENT PUBLICATION BY CULLGEN CO-FOUNDERS JIAN JIN AND YUE XIONG IN NATURE REVIEWS CANCER
SAN DIEGO, California, USA, June 16, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that Drs. Jian Jin and Yue Xiong, co-founders of Cullgen, have published a review of targeted protein degradation technology as well as a comprehensive summary of degraders in development for the treatment of cancer in the prestigious journal, Nature Reviews Cancer.
June
10
2021
CULLGEN APPOINTS MARK DEEG TO LEAD CLINICAL DEVELOPMENT
SAN DIEGO, California, USA, June 10, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that Mark Deeg, M.D., Ph.D., has joined the company as Executive Vice President of Clinical Development.
Feb
25
2021
CULLGEN CLOSES $50 MILLION SERIES B INVESTMENT TO ADVANCE TARGETED PROTEIN DEGRADERS AND NOVEL E3 LIGANDS PLATFORM
SAN DIEGO and SHANGHAI, February 25, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has closed a $50 million Series B financing.
Dec
03
2020
TARGETED PROTEIN DESTRUCTION: ADVANCES IN PROTACS OTHER DEGRADERS
December 3, 2020 Cullgen featured in targeted protein degradation article in Genetic Engineering & Biotechnology News
Oct
15
2020
CULLGEN ANNOUNCES “FEATURED ARTICLE” PUBLICATION OF FIRST IN CLASS TRK PROTEIN DEGRADERS IN JOURNAL OF MEDICINAL CHEMISTRY
October 15, 2020 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.
Apr
06
2020
CULLGEN ANNOUNCES PUBLICATION OF SMALL MOLECULE BRAF PROTEIN DEGRADERS IN JOURNAL OF MEDICINAL CHEMISTRY
April 6, 2020 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key BRAF mutant proteins has been accepted for publication by the Journal of Medicinal Chemistry.
Dec
10
2019
CULLGEN ANNOUNCES KEY PUBLICATION BY CULLGEN CO-FOUNDER JIAN JIN IN NATURE CHEMICAL BIOLOGY
December 10, 2019 Cullgen Inc., a biotechnology company developing small molecule therapeutics based on targeted protein degradation technology (commonly known as PROTAC), today announced that Dr. Jian Jin, a co-founder of Cullgen, has designed a novel targeted protein degrader that may be able to stop the growth of triple-negative breast cancer, a type of breast cancer for which there are few viable treatment options, according to a study recently published in Nature Chemical Biology entitled “Discovery of a first-in-class EZH2 selective degrader”.
Sept
09
2019
CULLGEN: BOOSTING THE BREADTH OF E3 LIGASES FOR PROTEIN DEGRADATION
September 9, 2019 Cullgen Emerging Company Profile published by BioCentury
Apr
10
2019
CULLGEN RECEIVES $16 MILLION SERIES A INVESTMENT TO ADVANCE PIPELINE OF TARGETED PROTEIN DEGRADERS
April 10, 2019 Series A financing led by two leading global venture capital firms – Sequoia Capital China and HighLight Capital.
July
CULLGEN ANNOUNCES EXPANDED SCIENTIFIC ADVISORY BOARD
DELAWARE, July 18, 2018 Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination), announced that Dr. Timothy Heffernan and Dr. Michele Pagano have joined the Company’s Scientific Advisory Board (SAB).
18
2018
July
11
2018
EXECUTIVES OF CULLGEN TO PRESENT AT INTERNATIONAL CONFERENCES
DELAWARE, July 11, 2018 Executives of Cullgen Inc. ("Cullgen") have been invited to present research findings at three international drug discovery conferences in US and China.
Apr
CULLGEN ANNOUNCES PUBLICATION BY CO-FOUNDERS IN EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
DELAWARE, April 3, 2018 Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian Jin and Dr. Yue Xiong, have published an article in European Journal of Medicinal Chemistry featuring first-in-class small-molecule degraders of Anaplastic Lymphoma Kinase.
03
2018
Mar
CULLGEN ANNOUNCES SEED FINANCING
TOKYO, March 1, 2018 Cullgen Inc. ("Cullgen") today announced a Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology.